Free Trial

Larimar Therapeutics (LRMR) Competitors

Larimar Therapeutics logo
$3.13 +0.25 (+8.75%)
As of 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LRMR vs. CRON, XERS, PHAR, REPL, VIR, GYRE, PHAT, NUVB, DNA, and DAWN

Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Cronos Group (CRON), Xeris Biopharma (XERS), Pharming Group (PHAR), Replimune Group (REPL), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry.

Larimar Therapeutics vs. Its Competitors

Cronos Group (NASDAQ:CRON) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Cronos Group has a net margin of 39.69% compared to Larimar Therapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Larimar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group39.69% -0.07% -0.07%
Larimar Therapeutics N/A -52.48%-46.08%

Cronos Group has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 7.3% of Cronos Group shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 17 more articles in the media than Cronos Group. MarketBeat recorded 20 mentions for Larimar Therapeutics and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.79 beat Larimar Therapeutics' score of 0.76 indicating that Cronos Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Larimar Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Cronos Group has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$124.59M6.18$41.08M$0.1315.35
Larimar TherapeuticsN/AN/A-$80.60M-$1.49-2.10

Larimar Therapeutics has a consensus target price of $18.50, indicating a potential upside of 490.68%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Larimar Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Cronos Group beats Larimar Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LRMR vs. The Competition

MetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$198.81M$2.42B$5.50B$8.93B
Dividend YieldN/A1.79%5.38%4.12%
P/E Ratio-2.088.9426.2519.86
Price / SalesN/A665.31415.14113.78
Price / CashN/A154.3736.4957.06
Price / Book1.164.548.055.38
Net Income-$80.60M$31.16M$3.16B$248.50M
7 Day Performance-3.63%0.15%1.78%2.78%
1 Month Performance42.36%8.74%4.74%5.84%
1 Year Performance-59.38%2.17%35.81%20.06%

Larimar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LRMR
Larimar Therapeutics
1.8852 of 5 stars
$3.13
+8.8%
$18.50
+490.7%
-65.0%$198.81MN/A-2.0830
CRON
Cronos Group
2.552 of 5 stars
$1.91
+0.5%
N/A-16.5%$736.65M$117.61M14.69450
XERS
Xeris Biopharma
4.0977 of 5 stars
$4.67
-0.6%
$6.25
+33.8%
+114.7%$730.30M$203.07M-15.57290Positive News
PHAR
Pharming Group
2.9108 of 5 stars
$10.68
-2.9%
$30.00
+181.0%
+30.4%$726.29M$297.20M-53.38280High Trading Volume
REPL
Replimune Group
3.9951 of 5 stars
$9.29
-0.4%
$20.83
+124.3%
-2.2%$719.22MN/A-3.03210
VIR
Vir Biotechnology
3.4319 of 5 stars
$5.04
-2.5%
$32.86
+551.9%
-43.8%$696.73M$74.21M-1.19580Positive News
GYRE
Gyre Therapeutics
0.2919 of 5 stars
$7.35
-0.9%
N/A-38.0%$689.14M$105.76M367.6840
PHAT
Phathom Pharmaceuticals
4.04 of 5 stars
$9.59
-1.5%
$17.50
+82.5%
-18.1%$669.48M$55.25M-1.83110
NUVB
Nuvation Bio
3.4413 of 5 stars
$1.96
+1.3%
$7.17
+266.6%
-38.7%$665.21M$7.87M-0.8360Gap Up
High Trading Volume
DNA
Ginkgo Bioworks
0.8177 of 5 stars
$11.29
+19.3%
$5.77
-48.9%
N/A$660.80M$227.04M-1.23640
DAWN
Day One Biopharmaceuticals
2.1324 of 5 stars
$6.50
+0.5%
$30.57
+370.3%
-51.3%$658.84M$131.16M-9.1560Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:LRMR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners